Elizabeth Scannell, MD
Allergy & Immunology · Winston Salem, NCNPI 1952369571
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 553 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by AstraZeneca at 25.3% of the total.
Across 553 payments — averaging $21.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Regeneron Healthcare Solutions, Inc.$2K
- GSK$1K
- Novartis$828
- Sanofi$796
- Genentech USA, Inc.$430
- plus $4K from 29 others
What the payments were for
- Food & beverage$11,82098%
- Education$1882%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 97 | $3,034 |
| Regeneron Healthcare Solutions, Inc. | 75 | $1,658 |
| GSK | 76 | $1,354 |
| Novartis | 43 | $828 |
| Sanofi | 57 | $796 |
| Genentech USA, Inc. | 10 | $430 |
| Kaleo, Inc. | 25 | $420 |
| AbbVie | 17 | $403 |
| Optinose US, Inc. | 26 | $383 |
| Pfizer | 18 | $294 |
| Amgen | 10 | $290 |
| Teva Pharmaceuticals USA, Inc. | 16 | $248 |
| CSL Behring | 9 | $235 |
| ARS Pharmaceuticals Operations, Inc. | 13 | $193 |
| Organon | 6 | $177 |
| Lilly USA, LLC | 5 | $167 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $134 |
| Aytu Biopharma, Inc. | 6 | $118 |
| Pharming Healthcare, Inc. | 5 | $101 |
| Incyte Corporation | 1 | $91 |
| Covis Pharma GmbH | 6 | $87 |
| Biocryst US Sales Co., LLC | 5 | $82 |
| Galderma Laboratories, L.p. | 3 | $67 |
| Sanofi-aventis U.S. LLC | 1 | $58 |
| Hospira, Inc. | 3 | $57 |
| Octapharma USA, Inc. | 2 | $55 |
| Grifols USA, LLC | 3 | $47 |
| Hikma Pharmaceuticals USA | 3 | $45 |
| Aimmune Therapeutics, Inc. | 2 | $37 |
| Alk-abello, Inc | 2 | $30 |
| Merck | 2 | $25 |
| Boehringer Ingelheim | 1 | $22 |
| Alcon | 1 | $17 |
| USWM, LLC | 1 | $15 |
| Tersera Therapeutics LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,008 in reported general payments places this provider in the 70th percentile of 140 allergy & immunology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucalaMepolizumab | 13 | $48,281 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $17,346 |
| Epinephrine | 59 | $11,788 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $10,176 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $10,160 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $2,965 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 21 | $2,955 |
| Arnuity ElliptaFluticasone Furoate | 11 | $2,804 |
| Azelastine Hcl | 65 | $1,801 |
| Wixela InhubFluticasone Propion/Salmeterol | 13 | $1,464 |
| Famotidine | 80 | $1,272 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 52 | $1,234 |
| Montelukast Sodium | 134 | $831 |
| Ventolin HfaAlbuterol Sulfate | 15 | $807 |
| Ipratropium Bromide | 22 | $596 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,354 | $78,59262 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $3,034 | $13,14128 claims |
| Hikma Pharmaceuticals USAEpinephrine | $45 | $11,78859 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 140 allergy & immunology providers in North Carolina.
Other allergy & immunology in Winston Salem
- Joel HartmanWinston Salem$749K
- Holly McPhersonWinston Salem$179K
- Kent NastasiWinston Salem$31K
- Ingrid HoffmannWinston Salem$9K
- Jason CaldwellWinston Salem$9K
- Maeve OconnorCharlotte$2.2M
- Cristine RadojicicDurham$558K
- Scott ComminsChapel Hill$555K
- William McCannAsheville$486K
- Aerik WilliamsSalisbury$298K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.